TORONTO, Aug. 2, 2022 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN)(OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic application, announces that it has appointed Richard Goldstein, currently serving as Canntab's CFO, as interim CEO of Canntab, effective July 31, 2022.
Read more at newswire.caCANNTAB ANNOUNCES APPOINTMENT OF RICHARD GOLDSTEIN AS INTERIM CEO
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here